Rivaroxaban for the treatment of superficial vein thrombosis, experience at King's College Hospital.

All patients had an isolated SVT confirmed by compression ultrasonography.8 The primary efficacy outcome was SVT, DVT, or PE within 90 days of diagnosis. Keywords: rivaroxaban; superficial vein thrombosis; anticoagulants; factor Xa inhibitor EN rivaroxaban superficial vein thrombosis anticoagulants factor Xa inhibitor e3 e6 4 12/27/21 20220101 NES 220101 The precise incidence of superficial vein thrombosis (SVT) is unknown. Bleeding was defined using the International Society on Thrombosis and Haemostasis criteria.9 Baseline characteristics and outcome data were extracted from the local hospital electronic patient record (EPR; Allscripts Sunrise™, Chicago, IL, USA), and anti-coagulation clinic database (DAWN xs) for each patient. [Extracted from the article]